r.iyer99/100
Storage condition for the stability statement stated on the certificate. Peptide content 99.5%. Research use. Not approved for human administration.
CPC — Chinese Peptide Company Co., Ltd.
Hangzhou, CN · established 2001. The index holds 227 assay reports across 40 batches and 27 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where CPC sells
Chinese Peptide Company Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit CPC at chinesepeptidecompany.net →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Chinese Peptide Company Co., Ltd.
- Short code in this index
- CPC
- Also known as
- CPC · CPC Biotech · Chinese Peptide Company
- City
- Hangzhou
- Region
- Hangzhou
- Country
- CN
- Established
- 2001
- First record in index
- 28 Jan 2024
- Most recent record
- 08 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.1%
n=227
Retail, shipped to the buyer
64.3%
n=227
Direct to the laboratory
17.2%
n=227
Median courier leg, direct despatch
7d
n=39
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 32 | 14.1% |
| Retail purchase, shipped to the buyer | 122 | 53.7% |
| Retail purchase via a third-party forwarder | 24 | 10.6% |
| Supplier despatch direct to the laboratory | 39 | 17.2% |
| Laboratory retained-sample archive | 10 | 4.4% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 227 CPC records the index holds, 32 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 15 of the 27 compounds CPC is represented by here — TB-500, GHRP-6, Ipamorelin, KPV, Semax, Tirzepatide and 9 further compounds. Those are the CPC lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for CPC. 32 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is CPC's own reviewers: 4 of the 26 on-record reviews state a quoted window and what happened against it. Where CPC despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 39 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.49%
n=220
Interquartile range
0.80pp
n=220
10th percentile
97.33%
n=220
Pass rate vs index spec
65.5%
n=220
Median recovery vs claim
97.5%
n=116
Median water
5.28%
n=227
Median |mass error|
2.8ppm
n=182
Records carrying a flag
32.2%
n=227
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.58pp
n=33
Index median spread
0.67pp
n=28
Lots tested 3+ times
33
n=40
Across the 33 CPC lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.58 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.06pp
n=39
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
54%
n=39
Divergences beyond 1 pp
0%
n=39
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.45%
n=172
Supplier-supplied median
98.71%
n=38
Supplier-supplied share of records
17.2%
n=227
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of CPC batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
68/100
n=40
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 53% | 25 points | |
| Peptide content stated | 63% | 20 points | |
| Endotoxin stated | 13% | 15 points | |
| Named impurities rather than a total | 21% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Tirzepatide | Incretin | 22 | 97.71 | 98.55 | -0.84 | 97.0 | 64 |
| Ipamorelin | Growth-hormone | 20 | 98.50 | 99.47 | -0.97 | 99.0 | 30 |
| GHRP-6 | Growth-hormone | 18 | 99.80 | 99.54 | +0.26 | 99.0 | 100 |
| TB-500 | Tissue-repair | 15 | 98.64 | 99.53 | -0.89 | 98.5 | 60 |
| BPC-157 | Tissue-repair | 14 | 98.71 | 99.16 | -0.45 | 98.0 | 100 |
| Semax | Neuroactive | 14 | 98.49 | 99.46 | -0.97 | 98.5 | 50 |
| GHK-Cu | Tissue-repair | 11 | 98.25 | 98.56 | -0.31 | 97.0 | 100 |
| KPV | Tissue-repair | 11 | 98.31 | 99.64 | -1.33 | 99.0 | 9 |
| Liraglutide | Incretin | 8 | 97.27 | 99.00 | -1.72 | 97.5 | 25 |
| Retatrutide | Incretin | 8 | 97.00 | 98.37 | -1.37 | 96.5 | 100 |
| IGF-1 LR3 | Growth-hormone | 8 | 98.16 | 98.28 | -0.13 | 95.0 | 100 |
| Semaglutide | Incretin | 8 | 98.44 | 98.89 | -0.45 | 97.0 | 100 |
| Kisspeptin-10 | Melanocortin-receptor | 8 | 98.66 | 99.28 | -0.62 | 98.5 | 88 |
| L-Glutathione (reduced) | Short | 7 n=7 | 98.36 | 99.33 | -0.97 | 98.5 | 29 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 7 n=7 | 98.75 | 99.49 | -0.74 | 98.5 | 100 |
| Selank | Neuroactive | 7 n=7 | 98.95 | 99.59 | -0.64 | 99.0 | 43 |
| Thymalin | Short | 7 n=7 | n<3 | — | — | 99.0 | — |
| N-Acetyl Semax Amide | Neuroactive | 6 n=6 | 98.99 | 99.35 | -0.36 | 98.5 | 100 |
| CJC-1295 (no DAC) | Growth-hormone | 5 n=5 | 97.82 | 99.09 | -1.27 | 98.0 | 0 |
| Hexarelin | Growth-hormone | 4 n=4 | 98.53 | 99.59 | -1.05 | 99.0 | 0 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 4 n=4 | 97.77 | 99.38 | -1.61 | 98.5 | 0 |
| L-Carnosine | Short | 3 n=3 | 98.95 | 99.58 | -0.63 | 99.0 | 33 |
| Gonadorelin | Hypothalamic | 3 n=3 | 98.84 | 99.12 | -0.28 | 98.5 | 100 |
| Pemvidutide | Incretin | 3 n=3 | 98.10 | 98.25 | -0.16 | 96.0 | 100 |
| Adipotide | Metabolic | 3 n=3 | 97.48 | 98.58 | -1.09 | 96.0 | 100 |
| SS-31 (Elamipretide) | Metabolic | 2 n=2 | n<3 | 99.53 | — | 98.5 | 100 |
| Thymosin α1 | Tissue-repair | 1 n=1 | n<3 | 99.40 | — | 97.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 17 | 98.44 | 97.54–99.02 | 4 |
| 2024-Q2 | 1 | 10 | 99.62 | 99.49–99.93 | 10 |
| 2024-Q3 | 1 | 1 | n<3 | — | 0 |
| 2024-Q4 | 1 | 8 | 98.66 | 98.37–99.53 | 1 |
| 2025-Q1 | 3 | 18 | 98.45 | 97.86–98.77 | 7 |
| 2025-Q2 | 5 | 26 | 98.88 | 97.28–99.76 | 17 |
| 2025-Q3 | 8 | 36 | 98.47 | 97.36–99.93 | 11 |
| 2025-Q4 | 3 | 15 | 99.76 | 97.79–99.93 | 2 |
| 2026-Q1 | 4 | 17 | 98.36 | 98.00–98.96 | 7 |
| 2026-Q2 | 7 | 49 | 98.29 | 96.52–99.59 | 8 |
| 2026-Q3 | 5 | 30 | 97.61 | 96.55–99.49 | 6 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 106 | 98.52 | +0.00 | 98.52 |
| PeptideMeter | 33 | 98.54 | -0.05 | 98.59 |
| Medutest | 41 | 98.44 | +0.08 | 98.36 |
| VendorInvestigate | 19 | 98.03 | -0.11 | 98.14 |
| Nordanalyt | 14 | 98.57 | +0.02 | 98.55 |
| Kestrel | 14 | 98.59 | +0.24 | 98.35 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
90.0/ 100565 ratings across the index network
an.restrepo98/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Regional stock held for the lines concerned.
n.fontaine96/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Further submissions on later lots would improve coverage.
ka.marchand95/100
Repeat determination at 9 months: 96.9%. Original: 96.9%. No drift detected in this sample.
f.aalto100/100
Quote correct at first issue on vial size, quantity and lead time. Price held to invoice.
h.nakamura99/100
Direct-supply material 99.5%. Intermediary vial, same nominal description, 99.2%. Identity confirmed by two orthogonal methods.
j.ostergaard97/100
Transit 8 days from stock held in the United States against a quoted 8. Customs documentation correct at first presentation.
a.hovland96/100
Labelling printed, lot and date legible on every unit examined. Regional stock held for the lines concerned. Figures as reported by the named service. Not reproduced by the index.
b.delgado97/100
Supplementary certificate for a lot released 24 months earlier retrieved from supplier records on request. Reorder at 18 months within 0.1 points of the original.
a.bergstrom92/100
Documentation complete at first issue. No supplementary request raised. Nothing unsecured in the consignment.
v.tulloch98/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid.
p.salgado100/100
Nine orders, tracking accurate at every hop on each. Contributor declares no interest beyond the transaction.
so.broberg96/100
Retention time assigned to the principal peak, printed. Catalogue availability matched the published catalogue.
k.hovland100/100
Cold chain intact, phase-change pack hard on arrival. Submitted to the index in full.
d.oyelaran99/100
Release signed and dated, named individual.
r.yilmaz95/100
3 orders, 14 months. No substitution, no reformulation, no post-payment unavailability. Documentation practice, not a single purity figure, is the substance here.
el.halonen97/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. Tracking record corresponded to consignment position at every hop.
n.trevino98/100
Consistency: 5 lots, purity band under 1.0 points wide.
so.demir100/100
Certificate carries a signature and a date from whoever released the batch. Complete against the index minimum data set at first issue.
s.aalto96/100
Cold chain intact. Phase-change pack solid at arrival, day 4.
vi.sjoberg98/100
Fill uniformity: 5 units weighed against declared fill, all within 2%. Not medical advice.
s.nkemelu97/100
Counter-ion identity and content answered quantitatively, one working day.
ay.ibarra100/100
Phase-change pack solid on arrival. Material returned 98.2%. Tracking record corresponded to consignment position at every hop. n=1, declared as n=1.
p.kravchenko95/100
Peptide content reported separately from chromatographic purity across all 8 certificates held. Identity confirmed by two orthogonal methods.
i.steiner99/100
Batch record supplied in full on request, attached rather than summarised. Record covers the lots named. Not generalised.
z.ivaturi98/100
Water content by Karl Fischer, method named. Contributor declares no interest beyond the transaction.
Block 12
Most recent records
Block 13
Contributor annotations on CPC records 444
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on CPC material are below, each linked to the record it sits on.
A beta-aspartyl isomer sits a tenth of a minute away and is mass-identical. That is the archetype of a pair where resolution is a compound property and no rule should adjudicate it.
Restricting every supplier comparison to buyer-sourced records is the sensitivity analysis the scorecards publish. On the current dataset it changes no ordering that was not already inside measurement noise.
Even a perfectly blind purchase is a lot somebody chose to test. Provenance fixes one selection problem and leaves the other standing.
Instrument class is on the record, which is what allows -2.2 ppm to be read at its proper weight. The index distinguishes "confirmed" from "consistent with" precisely on this field.
Coverage on this compound is thin enough that one record moves the class median visibly. That is a statement about the index rather than about the material, and it is why the n= badge sits beside every aggregate.
Spectral homogeneity across the main peak would complete this record. Mass confirms what eluted; the spectrum confirms that only one thing did.
Side-chain-modified compounds lose their linker readily in source, and a clean parent mass at +5.7 ppm indicates the ionisation conditions were gentle enough not to.
The supplier's own declaration is printed beside the index's balance on this page. Comparing the two is the point of publishing both and rule AX-R07 is about the comparison.
Every annotation the index holds on CPC material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what CPC itself publishes, open chinesepeptidecompany.net → alongside.
Block 14
Where to buy CPC
Chinese Peptide Company Co., Ltd. sells direct from chinesepeptidecompany.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the CPC store at chinesepeptidecompany.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.